Dr Sven Kili is the current Chief Executive Officer of Antion Biosciences, a company specializing in Multiplex Cell Engineering to develop smart-data-driven in-vivo allogeneic cell therapies for patients suffering from hard-to-treat diseases. Before his role at Antion Biosciences, he served as Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases, where he led the teams responsible for the development and commercialization of gene therapies for various rare genetic disorders. Some of these include Strimvelis®, the first ex-vivo gene therapy approved for children with ADA-SCID, as well as treatments for Wiskott-Aldrich Syndrome (WAS), Metachromatic Leukodystrophy (MLD), and Beta-Thalassemia. Dr Kili has also held the position of Senior Director, Cell Therapy and Regenerative Medicine at Sanofi (Genzyme) Biosurgery, where he led the clinical development, approval, and commercialization of the first combined ATMP product in the EU, MACI®.